TY - JOUR
T1 - Dose-dependent changes in auditory sensory gating in the prefrontal cortex of the cynomolgus monkey
AU - Huang, Hui
AU - Ya, Jinrong
AU - Wu, Zhe
AU - Wen, Chunmei
AU - Zheng, Suyue
AU - Tian, Chaoyang
AU - Ren, Hui
AU - Carlson, Synnöve
AU - Yu, Hualin
AU - Chen, Feng
AU - Wang, Jian Hong
PY - 2016/5/24
Y1 - 2016/5/24
N2 - Background: Sensory gating, often described as the ability to filter out irrelevant information that is repeated in close temporal proximity, is essential for the selection, processing, and storage of more salient information. This study aimed to test the effect of sensory gating under anesthesia in the prefrontal cortex (PFC) of monkeys following injection of bromocriptine, haloperidol, and phencyclidine (PCP). Material/Methods: We used an auditory evoked potential that can be elicited by sound to examine sensory gating during treatment with haloperidol, bromocriptine, and PCP in the PFC in the cynomolgus monkey. Scalp electrodes were located in the bilateral PFC and bilateral temporal, bilateral parietal, and occipital lobes. Administration of bromocriptine (0.313 mg/kg, 0.625 mg/kg, and 1.25 mg/kg), haloperidol (0.001 mg/kg, 0.01 mg/kg, and 0.05 mg/kg), and the N-methyl-D-aspartic acid receptor antagonist PCP (0.3 mg/kg) influenced sensory gating. Results: We demonstrated the following: (1) Administration of mid-dose bromocriptine disrupted sensory gating (N100) in the right temporal lobe, while neither low-dose nor high-dose bromocriptine impaired gating. (2) Low-dose haloperidol impaired gating in the right prefrontal cortex. Mid-dose haloperidol disrupted sensory gating in left occipital lobe. High-dose haloperidol had no obvious effect on sensory gating. (3) Gating was impaired by PCP in the left parietal lobe. Conclusions: Our studies showed that information processing was regulated by the dopaminergic system, which might play an important role in the PFC. The dopaminergic system influenced sensory gating in a dose- and regiondependent pattern, which might modulate the different stages that receive further processing due to novel information.
AB - Background: Sensory gating, often described as the ability to filter out irrelevant information that is repeated in close temporal proximity, is essential for the selection, processing, and storage of more salient information. This study aimed to test the effect of sensory gating under anesthesia in the prefrontal cortex (PFC) of monkeys following injection of bromocriptine, haloperidol, and phencyclidine (PCP). Material/Methods: We used an auditory evoked potential that can be elicited by sound to examine sensory gating during treatment with haloperidol, bromocriptine, and PCP in the PFC in the cynomolgus monkey. Scalp electrodes were located in the bilateral PFC and bilateral temporal, bilateral parietal, and occipital lobes. Administration of bromocriptine (0.313 mg/kg, 0.625 mg/kg, and 1.25 mg/kg), haloperidol (0.001 mg/kg, 0.01 mg/kg, and 0.05 mg/kg), and the N-methyl-D-aspartic acid receptor antagonist PCP (0.3 mg/kg) influenced sensory gating. Results: We demonstrated the following: (1) Administration of mid-dose bromocriptine disrupted sensory gating (N100) in the right temporal lobe, while neither low-dose nor high-dose bromocriptine impaired gating. (2) Low-dose haloperidol impaired gating in the right prefrontal cortex. Mid-dose haloperidol disrupted sensory gating in left occipital lobe. High-dose haloperidol had no obvious effect on sensory gating. (3) Gating was impaired by PCP in the left parietal lobe. Conclusions: Our studies showed that information processing was regulated by the dopaminergic system, which might play an important role in the PFC. The dopaminergic system influenced sensory gating in a dose- and regiondependent pattern, which might modulate the different stages that receive further processing due to novel information.
KW - Bromocriptine
KW - Dopamine
KW - Haloperidol
KW - Prefrontal cortex
KW - Sensory gating
UR - http://www.scopus.com/inward/record.url?scp=84970953987&partnerID=8YFLogxK
U2 - 10.12659/MSM.898938
DO - 10.12659/MSM.898938
M3 - Article
C2 - 27218151
AN - SCOPUS:84970953987
VL - 22
SP - 1752
EP - 1760
JO - Medical Science Monitor
JF - Medical Science Monitor
SN - 1234-1010
ER -